mRNA Therapeutics Market Size, Growth, Demands Outlook and Forecasts to 2030

 According to the research report, the global mRNAtherapeutics size is expected to touch USD 128.14 Billion by 2030, from USD42.56  Billion in 2021, growing with a significant CAGR of 13.03% from 2022 to 2030. 

The mRNA therapeutics market report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global mRNA therapeutics market in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global mRNA therapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global mRNA therapeutics market during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link https://www.precedenceresearch.com/sample/2118

 Report Scope of the mRNA therapeutics Market

Report Coverage	Details
Market Size in 2022	USD 48.1 Billion
Market Size by 2030	USD 128.14 Billion
Growth Rate from 2022 to 2030	CAGR of 13.03%
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Application, Type, End User, and Geography

This study covers a detailed segmentation of the global mRNA therapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global mRNA therapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• Alnylam Pharmaceuticals
• Arcturus Therapeutics
• Argos Therapeutics Inc.
• AstraZeneca plc.
• BioNTech SE
• CRISPR Therapeutics AG 
• Curevac AG
• Etherna Immunotherapies
• Ethris GMBH
• GSK plc.
• IN-CELL-ART
• Ionis Pharmaceuticals, Inc
• Moderna Therapeutics
• Nutcracker
• Pfizer Inc.
• Sangamo Therapeutics, Inc.
• Sanofi AG
• Sarepta Therapeutics
• Tiba Biotech
• Translate Bio, Inc.

Market Segmentation

 By Application

• Rare Genetic Diseases
• Oncology
• Respiratory Diseases
• Infectious Diseases
• Others

By Type

• Prophylactic Vaccines
• Therapeutic Vaccines
• Therapeutic Drugs

By End User

• Hospitals & Clinics
• Research Organizations
• Other

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Research Methodology

The research methodology adopted by analysts for compiling the global mRNA therapeutics market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global mRNA therapeutics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on MRNA Therapeutics Market 

5.1. COVID-19 Landscape: MRNA Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global MRNA Therapeutics Market, By Application

8.1. MRNA Therapeutics Market, by Application, 2022-2030

8.1.1 Rare Genetic Diseases

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Oncology

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Respiratory Diseases

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Infectious Diseases

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global MRNA Therapeutics Market, By Type

9.1. MRNA Therapeutics Market, by Type, 2022-2030

9.1.1. Prophylactic Vaccines

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Therapeutic Vaccines

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Therapeutic Drugs

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global MRNA Therapeutics Market, By End User 

10.1. MRNA Therapeutics Market, by End User, 2022-2030

10.1.1. Hospitals & Clinics

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Research Organizations

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Other

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global MRNA Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Application (2017-2030)

11.1.2. Market Revenue and Forecast, by Type (2017-2030)

11.1.3. Market Revenue and Forecast, by End User (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Application (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End User (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Application (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End User (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Application (2017-2030)

11.2.2. Market Revenue and Forecast, by Type (2017-2030)

11.2.3. Market Revenue and Forecast, by End User (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Application (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End User (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Application (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End User (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Application (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End User (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Application (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End User (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Application (2017-2030)

11.3.2. Market Revenue and Forecast, by Type (2017-2030)

11.3.3. Market Revenue and Forecast, by End User (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Application (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End User (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Application (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End User (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Application (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End User (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Application (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End User (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Application (2017-2030)

11.4.2. Market Revenue and Forecast, by Type (2017-2030)

11.4.3. Market Revenue and Forecast, by End User (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Application (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End User (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Application (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End User (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Application (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End User (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Application (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End User (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Application (2017-2030)

11.5.2. Market Revenue and Forecast, by Type (2017-2030)

11.5.3. Market Revenue and Forecast, by End User (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Application (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End User (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Application (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End User (2017-2030)

Chapter 12. Company Profiles

12.1. Alnylam Pharmaceuticals

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Arcturus Therapeutics

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Argos Therapeutics Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. AstraZeneca plc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. BioNTech SE

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. CRISPR Therapeutics AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Curevac AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Etherna Immunotherapies

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Ethris GMBH

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. GSK plc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com